TransCon hGH/TransCon CNP combination

June 08, 2026 — Ascendis Pharma A/S (Nasdaq: ASND) announced it will present new clinical and real-world data from its rare endocrinology programs at ENDO 2026 (Endocrine Society annual meeting; Chicago, June 13–16, 2026), including two oral presentations and three posters.

Key items include: final results from the Phase 3 PaTHway trial of palopegteriparatide (TransCon PTH) in adults with hypoparathyroidism (oral presentation); 156-week PaTHway results reporting improved work functioning and productivity in employed adults with chronic hypoparathyroidism (poster); and a systematic literature review/meta-analysis estimating global prevalence of chronic hypoparathyroidism (poster). In achondroplasia, Ascendis will present 52-week Phase 2 COACH trial results evaluating navepegritide (TransCon CNP) combined with lonapegsomatropin (TransCon hGH) in children (oral presentation). In pediatric growth hormone deficiency, a SkybriGHt registry analysis will report safety/effectiveness of lonapegsomatropin in the first 100 patients with 2 years follow-up (poster).

Business/clinical significance: the company is positioning longer-term efficacy, safety, and functional outcomes data across key rare endocrine indications ahead of peer-reviewed scientific audiences.